Browsing Tag
Amgen
62 posts
Amgen’s Blincyto gains EU approval for consolidation phase treatment in B-ALL
Amgen has received European Commission approval for Blincyto (blinatumomab) as part of consolidation therapy in adults with newly…
FDA approves Amgen’s BLINCYTO for expanded use in B-ALL treatment
Amgen (NASDAQ: AMGN) has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval…
COURSE trial reveals promising results for TEZSPIRE in COPD patients with high eosinophil counts
In a significant development in chronic obstructive pulmonary disease (COPD) management, the Phase IIa COURSE trial, a proof-of-concept…
Amgen seeks European approval for teprotumumab in thyroid eye disease
Amgen (NASDAQ: AMGN), a global biotechnology leader, has announced its plans to submit a Marketing Authorization Application (MAA)…
Quantinuum closes $300m equity fundraise, valued at $5bn pre-money
Quantinuum, a global leader in integrated quantum computing, has announced the closing of a substantial $300 million equity…
Glenmark Pharmaceuticals secures FDA approval for generic version of Otezla Tablets
Glenmark Pharmaceuticals Ltd. has successfully secured the final approval from the United States Food & Drug Administration (U.S.…
Amgen to acquire Irish biopharma company Horizon Therapeutics for $28bn
Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise…
Amgen to acquire American biopharma company ChemoCentryx for $3.7bn
Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases…
Liberty Mutual wraps up $515m acquisition of Malaysian insurer AmGeneral
Liberty Mutual Insurance has wrapped up the previously announced MYR 2.29 billion ($515 million) acquisition of AmGeneral Insurance…
Amgen, Generate Biomedicines sign $1.9bn worth research collaboration deal
Amgen has signed a research collaboration deal worth up to $1.9 billion with Cambridge-based Generate Biomedicines for the…